QUANTITATIVE ONCOLOGY Paul Spellman, PhD and Joe Gray, PhD, Program Co-Leaders ABSTRACT The Quantitative Oncology (QO) Program is a multi-disciplinary research program that was formed to facilitate the development and application of advanced measurement capabilities from omics to imaging, combined with computational techniques, to improve cancer management. The goal of the QO program is to enable quantitative understanding of the behavior of cancerous cells and tissues as they evolve, respond to therapy, and interact with their microenvironments. The QO program facilitates collaborative science organized around three research themes: 1) Imaging ? focuses on improving the understanding of cancer by analyzing components of tumors on scales from angstrom to centimeters, including proteins to cells to tissues and using this data to inform diagnostics and therapies; 2) Omics ? employing and improving tools to analyze genomes, transcriptomes, and proteomes to enhance our understanding of cancer; and 3) Systems Biology - focuses on elucidation of the emergent properties of cancer-related molecular networks, the molecular and cellular phenotypes they regulate and the evolution/adaptation of these systems during cancer development and treatment. The QO Program is co-led by Paul Spellman, PhD, an expert in the application of translational cancer genomics and systems biology to cancer detection and classification, and Joe Gray, PhD, an expert in systems biomedicine and imaging technologies, with an emphasis on breast and pancreatic cancer. The QO program has 28 members who are drawn from seven basic science departments and four clinical departments in the OHSU School of Medicine, and the Pacific Northwest National Laboratory (PNNL). Annual direct cost funding as of January 2016 amounted to $10,011,427 (total cost), of which $1,833,130 (total cost) was from the NCI and $6,229,652 (total cost) was peer-reviewed. The discoveries made in this program have resulted in 251 publications, of which 31.5% are intra-programmatic collaborations, 43.8% are inter-programmatic collaborations, and 71.3% are inter- institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-19
Application #
9278530
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
19
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198

Showing the most recent 10 out of 277 publications